Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Filip Janku, MD, PhD, Anderson Cancer Center, The University of Texas, Houston, TX, outlines the use of SB 11285, a novel STING agonist, and nivolumab, a human immunoglobulin G4 monoclonal antibody for the treatment of solid tumors. This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.